Abstract:Objective: To develop and validate a risk scoring tool to identify those who are at increased risk of chlamydia infection. Methods: We used demographic data, sexual behaviour information and chlamydia positivity results from more than 45 000 individuals who attended Sydney Sexual Health Centre between 1998 and 2009. Participants were randomly allocated to either the development or internal validation data set. Using logistic regression, we created a prediction model and weighted scoring system using the development data set and calculated the odds ratio of chlamydia positivity for participants in successively higher quintiles of score. The internal validation data set was used to evaluate the performance characteristics of the model for five quintiles of risk scores including population attributable risk, sensitivity and specificity. Results: In the prediction model, inconsistent condom use, increased number of sexual partners in last 3 months, genital or anal symptoms and presenting to the clinic for sexually transmitted infections screening or being a contact of a sexually transmitted infection case were consistently associated with increased risk of chlamydia positivity in all groups. High scores (upper quintiles) were significantly associated with increased risk of chlamydia infection. A cut-point score of 20 or higher distinguished a increased risk group with a sensitivity of 95%, 67% and 79% among heterosexual men, women and men who have sex with men (MSM), respectively. Conclusion: The scoring tool may be included as part of a health promotion and/or clinic website to prompt those who are at increased risk of chlamydia infection, which may potentially lead to increased uptake and frequency of testing. INTRODUCTION Chlamydia infection is highly prevalent in young heterosexuals and men who have sex with men (MSM) in Australia, with prevalence estimates of 3e5% in both populations. 2 The majority of chlamydia infections are asymptomatic. Chlamydia is associated with sequelae such as pelvic inflammatory disease and infertility in women and proctitis in men. Also in MSM, chlamydia re-infection of the rectum has been associated with an increased risk of HIV seroconversion. The number of chlamydia notifications continues to increase steadily each year among MSM and young heterosexual men and young women in Australia, 9 as in many other countries. A major public health challenge is therefore to identify individuals at risk of chlamydia and facilitate testing and treatment before the development of chlamydia sequelae and onward transmission to To cite: Wand H, Guy R, Donovan B, et al. Developing and validating a risk scoring tool for chlamydia infection among sexual health clinic attendees in Australia: a simple algorithm to identify those at high risk of chlamydia infection. BMJ Open 2011;1:e000005. doi:10.1136/bmjopen-2010000005 < Prepublication history for this paper is available online. To view these files please visit the journal online (http:// bmjopen.bmj.com). Received 26 September 2010 Accepted 6 January 2011 This final article is available for use under the terms of the Creative Commons Attribution Non-Commercial 2.0 Licence; see http://bmjopen.bmj.com National Centre in HIV Epidemiology and Clinical Research, Sydney, New South Wales, Australia Sydney Sexual Health Centre, Sydney, New South Wales, Australia National Centre in HIV Social Research, University of New South Wales, Sydney, New South Wales, Australia Correspondence to Dr Handan Wand; hwand@nchecr.unsw.edu.au ARTICLE SUMMARY Article focus The authors created a risk assessment tool that allows people to estimate their own chlamydia risk score based on simple non-invasive variables. Key messages The tool described here will potentially provide a simple and cost-effective method of identifying and alerting individuals who would benefit from chlamydia screening. This tool may be included as part of a health promotion and/or clinic website. This tool may potentially lead to increased uptake and frequency of testing. Strengths and Limitations This is the first study to utilize statistical methods to derive a locally-specific assessment tool using 12 years of data from more than 45 000 men and women. The Study population was sexual health clinic attendees who are likely to be at higher risk for Chlamydia infection compared to the general population. Wand H, Guy R, Donovan B, et al. BMJ Open 2011;1:e000005. doi:10.1136/bmjopen-2010-000005 1 Open Access Research group.bmj.com on June 12, 2017 Published by http://bmjopen.bmj.com/ Downloaded from

Clopidogrel(TM): an alternative to acetylsalicylic acid and ticlopidine in antiplatelet therapy?

The osteocyte as a therapeutic target in the treatment of osteoporosis

Nano biomaterials based strategies for enhanced brain targeting in the treatment of neurodegenerative diseases: an up-to-date perspective

Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance

Recent advances in nanotechnology and its application for neuro-disease: a review

Nanotechnological advancement for the treatment of neurodegenerative disorders

Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders

White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia

Cell-Membrane-Coated Nanoparticles for Targeted Drug Delivery to the Brain for the Treatment of Neurological Diseases

Effect of acoustic tumor extension into the internal auditory canal on distortion-product otoacoustic emissions.

Herbal-based nanosystems: A novel drug-delivery treatment procedure against neurodegenerative disorders

Nano-Neurotheranostics: Impact of Nanoparticles on Neural Dysfunctions and Strategies to Reduce Toxicity for Improved Efficacy

chlamydia infection algorithm to identify those at high risk of clinic attendees in Australia : a simple for chlamydia infection among sexual health Developing and validating a risk scoring tool

Nanoparticle Formulations for the Improvement of Symptomatic Treatments of Neurodegenerative Disorders

Harnessing Two-Dimensional Nanomaterials for Diagnosis and Therapy in Neurodegenerative Diseases: Advances, Challenges and Prospects

Nanotechnology-driven Microemulsion Based Intranasal Delivery to Neurotechnology-driven Neuralink: Strategies to Improve Management of Neurodegenerative Disorders

Nanomaterial-enabled drug transport systems: a comprehensive exploration of current developments and future avenues in therapeutic delivery

Intraoperative localisation of a urachal bladder tumour prior to partial cystectomy.

Nanoparticles of Herbal Extracts in Treatment of Neurodegenerative Disorders

Recent Status of Nanomaterial Fabrication and Their Potential Applications in Neurological Disease Management

Nanoparticle-based Gene Therapy for Neurodegenerative Disorders